not-yet-known not-yet-known not-yet-known unknown The primary goal of this study is to identify an effective treatment for SARS-CoV-2. Our research was conducted in three phases: 1. Molecular Docking Analysis: We investigated the potential of artemisinin and its derivative to block viral entry by targeting the SARS-CoV-2 spike protein and RNA-dependent RNA polymerase (RDRP) using bioinformatics methods. 2. In Vitro Assays: We evaluated the antiviral efficacy of these compounds through SARS-CoV-2 neutralization and cytopathic effect (CPE) assays. 3. Clinical Trials: We assessed the therapeutic impact of Annual SZ®, a combination of artemisinin and its derivative, on COVID-19 patients by monitoring clinical symptoms (PCR test, dyspnea, cough, fever, oxygen saturation levels) and inflammatory markers (ESR, CRP, CBC, IL-6, and IFN-γ). Patients were divided into two groups: one receiving the standard treatment protocol and the other receiving Annual SZ® in addition to standard care. The molecular docking results revealed that artemisinin binds to the RBD of the spike protein (binding energy: -163.805 kJ/mol), while its derivative interacts with nsp8, a cofactor of RNA polymerase, inhibiting viral replication (binding energy: -70 kJ/mol). In vitro assays demonstrated that artemisinin effectively disrupted the spike-ACE2 interaction, and its derivative reduced CPE in SARS-CoV-2-infected Vero cells in a dose-dependent manner. Clinical trials showed a statistically significant improvement (p < 0.05) in disease severity in patients treated with Annual SZ®, including: Reduced symptoms such as dry cough, shortness of breath, and chest pain Improved oxygen saturation levels (SpO2). Decreased IL-6 levels (p < 0.05) and an increase in IFN-γ levels (p > 0.05) These findings suggest that Annual SZ® has anti-inflammatory and antiviral properties, making it a promising candidate for COVID-19 treatment. Further studies with larger sample sizes are required to validate its long-term efficacy and safety.